Last reviewed · How we verify
Daunorubicin/Idarubicin
Daunorubicin and idarubicin are anthracycline chemotherapy agents that intercalate into DNA and inhibit topoisomerase II, leading to DNA strand breaks and cancer cell death.
Daunorubicin and idarubicin are anthracycline chemotherapy agents that intercalate into DNA and inhibit topoisomerase II, leading to DNA strand breaks and cancer cell death. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML).
At a glance
| Generic name | Daunorubicin/Idarubicin |
|---|---|
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Drug class | Anthracycline chemotherapy agent |
| Target | Topoisomerase II; DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Both drugs are anthracycline antibiotics that work by intercalating between DNA base pairs and inhibiting topoisomerase II, an enzyme essential for DNA replication and transcription. This dual mechanism causes double-strand DNA breaks and prevents cancer cell proliferation. They are particularly effective against rapidly dividing hematologic malignancies.
Approved indications
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Chronic myeloid leukemia (CML)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Cardiotoxicity (dose-dependent)
- Nausea and vomiting
- Mucositis
- Alopecia
- Infection
Key clinical trials
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (PHASE1)
- BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (PHASE2)
- CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics (PHASE2)
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) (PHASE2)
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML (PHASE3)
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: